Clinical Trials

136 enrolled 29 charts

Prostatic Neoplasms, Castration-Resistant

NCT04497844 2026-05-11

AMPLITUDE

696 enrolled 15 charts 1 FDA

Metastatic Castration-sensitive Prostate Cancer

NCT04502602 2026-05-11

iNNOVATE

18 enrolled

Ovarian Neoplasms

NCT05689021 2026-05-11

CJNJ-67652000 and Prednisone for Treatment of Metastatic Castration-Resistant Prostate Cancer and SPOP Gene Mutations

8 enrolled

Prostatic Neoplasms

NCT03748641 2026-05-08

MAGNITUDE

765 enrolled 16 charts 1 FDA

Prostatic Neoplasms, Castration-Resistant

NCT04577833 2026-05-08

A Study of Comparative Formulations of Niraparib and Abiraterone Acetate (AA) in Men With Prostate Cancer

136 enrolled

Prostatic Neoplasms

NCT04170153 2026-05-07

Tuvusertib (M1774) in Participants With Metastatic or Locally Advanced Unresectable Solid Tumors (DDRiver Solid Tumors 301)

161 enrolled

Tumor-Agnostic

Neoplasm Metastasis

NCT06212583 2026-05-06

KNIGHTS

88 enrolled

Prostatic Neoplasms

NCT04194554 2026-05-01

ASCLEPIuS

102 enrolled

Prostatic Neoplasms

NCT03768063 2026-04-28

IMbrella B

1,000 enrolled

Tumor-Agnostic

Neoplasms

NCT06077877 2026-04-24

A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK), and Preliminary Anticancer Activity of GSK4524101 Alone or With Niraparib in Participants With Solid Tumors

42 enrolled

Tumor-Agnostic

Neoplasms

NCT04701307 2026-04-22

Niraparib and Dostarlimab for the Treatment of Small Cell Lung Cancer and Other High-Grade Neuroendocrine Carcinomas

48 enrolled

EndocrineThoracic

Lung Neoplasms, Carcinoma, Neuroendocrine, Small Cell Lung Carcinoma

NCT05335993 2026-04-03

A Clinical Study Evaluating a Combination of Oregovomab and Niraparib in Adult Women With Platinum Sensitive Recurrent Ovarian Cancer.

10 enrolled

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT03586661 2026-03-11

Niraparib and Copanlisib in Treating Patients With Recurrent Endometrial, Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

31 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms, Disease Progression

NCT02655016 2026-03-10

A Study of Niraparib (GSK3985771) Maintenance Treatment in Participants With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy

733 enrolled 21 charts 1 FDA

Phase EARLY_PHASE1 Active not recruiting

Ovarian Neoplasms

NCT05076513 2026-03-09

Trial of Niraparib in Participants With Newly-diagnosed Glioblastoma and Recurrent Glioma

42 enrolled

Glioblastoma, Glioma

NCT06433219 2026-02-18

Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC 302)

63 enrolled

Hereditary Sensory and Autonomic Neuropathies, Ovarian Neoplasms

NCT03830918 2026-02-12

Niraparib, Temozolomide and Atezolizumab in Treating Patients With Advanced Solid Tumors and Extensive-Stage Small Cell Lung Cancer With a Complete or Partial Response to Platinum-Based First-Line Chemotherapy

59 enrolled

Thoracic

Lung Neoplasms, Small Cell Lung Carcinoma

NCT04068753 2026-02-10

STAR

66 enrolled

Phase EARLY_PHASE1 Active not recruiting

Uterine Cervical Neoplasms

NCT05406700 2026-02-09

Niraparib In Recurrent IDH 1/2 Gliomas

16 enrolled

Glioma

NCT03368729 2026-01-23

Niraparib in Combination With Trastuzumab in Metastatic HER2+ Breast Cancer

46 enrolled

Breast Neoplasms

NCT04992013 2026-01-23

Niraparib in Tumors Metastatic to the CNS

20 enrolled

Neoplasm Metastasis, Central Nervous System Neoplasms

NCT04673448 2026-01-09

Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal Cancer

BreastGastrointestinalGynecologic

18 enrolled

Breast Neoplasms, Fallopian Tube Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms

NCT04221503 2026-01-08

Niraparib/TTFields in GBM

30 enrolled

Glioblastoma

NCT03983993 2026-01-05

NIPAVect

26 enrolled 8 charts

Gastrointestinal

Colorectal Neoplasms

NCT03602859 2025-12-31

FIRST

1,400 enrolled 18 charts

Ovarian Neoplasms

NCT04592237 2025-12-23

Cabazitaxel, Carboplatin, and Cetrelimab Followed by Niraparib With or Without Cetrelimab for the Treatment of Aggressive Variant Metastatic Prostate Cancer

120 enrolled

Prostatic Neoplasms

NCT05515575 2025-10-20

A Study of Niraparib in People With Soft Tissue Sarcoma Who Have Changes in Their Tumor DNA

8 enrolled

Sarcoma

NCT04837209 2025-10-01

NADiR

32 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT03945721 2025-09-29

UNITY

21 enrolled

Breast Neoplasms, Neoplasm, Residual, Triple Negative Breast Neoplasms

NCT03981796 2025-09-03

RUBY

785 enrolled 2 FDA

Neoplasms, Recurrence

NCT04915755 2025-07-16

ZEST

40 enrolled 13 charts

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT04507841 2024-12-17

Niraparib for the Neoadjuvant Treatment of Unresectable Ovarian Cancer

67 enrolled

Ovarian Neoplasms

NCT04185831 2024-08-22

MEGALiT